Title:Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies
VOLUME: 17 ISSUE: 5
Author(s):Haixing Guan, Yongli Du*, Weiwei Han, Jingkang Shen* and Qunyi Li
Affiliation:School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology, 3501 Daxue Road, Jinan 250353, School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology, 3501 Daxue Road, Jinan 250353, School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology, 3501 Daxue Road, Jinan 250353, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, Clinical Pharmacy Laboratory, Huashan Hospital, Fudan University, 12 Wu Lu Mu Qi M Road, Shanghai 200040
Keywords:Anti-cancer agents, cell cycle, clinical trials, cyclin-dependent kinases 4, selective inhibitors, structure activity relationship
(SAR).
Abstract:Cyclin-Dependent Kinases 4 (CDK4) belongs to a family of serine-threonine protein kinase and plays key
regulatory role in G1-phase of cell cycle progression. Compelling evidences have shown that targeting CDK4
pathway is an attractive proposition for tumor therapy. Recent progresses of selective small molecule CDK4
inhibitors in cancer therapy have endorsed the field to be interested and attractive. In this review, we will discuss the
recent developments of CDK4 inhibitors on several aspects such as the structure of CDK4, the working mechanism
of CDK4 inhibitors, the structure activity relationships (SARs) of the selective CDK4 inhibitors and the latest
developments of the selective CDK4 inhibitors in clinical trials.
